IL2 and renal cell carcinoma: Importantly, RCC is not sensitive to radiotherapy and chemotherapy; the traditional treatment of advanced RCC is based on IL‐2 and IFN‐α immunotherapy, but the effective rate for patients is only 5–27%, and the adverse effects are great; in recent years, a series of targeted drugs has been developed and rapidly applied in clinic 3.